폐암 (NSCLC)

172개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved172 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

bevacizumab (Avastin)

US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indicatio… · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1444Status Approved
AntibodyCurated CoreFDAstaleBristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDAstaleAstraZenecaApproved

durvalumab (Imfinzi, MEDI4736)

NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 750Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, TDxd)

HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow brea… · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 243Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd)

HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior thera… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
AntibodyCurated CoreFDAstaleAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
ADCCurated CoreFDAstaleAbbVieMMAE (microtubule inhibitor)Approved

telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv)

Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression · c-Met

#c-Met#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
AntibodyLimited DatastaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 155Status Recruiting
ADCLimited DatastaleDaiichi Sankyo Co., Ltd.Phase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 149Status Recruiting
ADCLimited DatastaleDaiichi Sankyo Co., Ltd.deruxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 148Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 141Status Active
AntibodyLimited DatastaleMerck KGaAPhase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 138Status Active
ADCLimited DatastaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 124Status Recruiting
AntibodyCurated CorestaleEli Lilly and CompanyPhase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 117Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 94Status Active
AntibodyLimited DatastaleRochePreclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#Popular#monoclonal-antibody+1
Trials 60Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#Popular#monoclonal-antibody+2
Trials 60Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCGovitecan in gynecologic ma…Phase 3

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan)

Non-small Cell Lung Cancer; Solid Tumors · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#Popular#antibody-drug-conjugate+5
Trials 57Status Recruiting

1 / 9 pages

← PreviousNext →